SILO Silo Pharma, Inc.
Research report · from SEC EDGAR · close 2026-07-31
$4.19 -1.4%
$68.2M mkt cap
executive summary
Silo Pharma, Inc. (SILO) is a $68.2M company. Revenue is $72,102 (+0.0% y/y) at a -5863% net margin. It is not yet profitable. Our health score is D (51/100). 2 red flags on file. It may need to raise cash (dilution risk).
Revenue (FY)
$72,102
+0.0% y/y
⛔Going-concern warning
Auditor flagged substantial doubt about the company continuing for the next 12 months — a raise is usually required.
⚠Weak fundamentals
Piotroski F-Score of 2/9 — most quality checks are failing.
who's buying
Insider buys / sells
0 / 0
Cash & ST investments
$6.0M
Operating cash flow
-$4.7M
Assembled from SEC EDGAR (XBRL, Form 4, 13F, filings), STOCK Act disclosures, and end-of-day prices — every figure is real and sourced; nothing is fabricated or predicted. Filings lag 40–90 days. Educational, not investment advice. Generated 2026-07-31 by stocktools.ai.